Figure 5.

Mepolizumab has no significant effect on IL-5–responsive cell surface activation markers on blood or BAL eosinophils. Forty-eight hours after segmental bronchoprovocation with allergen, the expression pattern of activation markers was assessed on blood eosinophils and on airway eosinophils obtained from the segment challenged with 20% of the participant’s AgPD₂₀ (allergen provocation dose resulting in a 20% reduction in FEV₁) (P values indicated above the solid lines). The differences in activation marker expression did not change after mepolizumab administration (P value indicated above the dashed lines). Data represent medians with first and third quartiles (CD44 and CD23, n = 8; CCR3, n = 7; CD69, n = 6). BAL = bronchoalveolar lavage; D2 = Day 2; FcεRII = low-affinity receptor for IgE; ns = not significant.